Table of Content

1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Prevalence of Infectious Diseases
4.2.2 Emergence of New Technologies, especially in Biologics
4.3 Market Restraints
4.3.1 Complex Complications Involved in the Diseases of Animal
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Anti-infectives
5.1.2 Anti-inflammatory
5.1.3 Parasiticides
5.1.4 Vaccines
5.1.5 Others
5.2 By Route of Administration
5.2.1 Oral
5.2.2 Parenteral
5.2.3 Topical
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bayer AG
6.1.2 Zoetis Inc.
6.1.3 Virbac S.A
6.1.4 Boehringer Ingelheim International GmbH (Merial)
6.1.5 Elanco
6.1.6 Ceva
6.1.7 Vetoquinol S.A
6.1.8 Bimeda, Inc (Bimeda Holdings PLC)
6.1.9 Merck & Co., Inc.


7 MARKET OPPORTUNITIES AND FUTURE TRENDS